When measured against the market's most prolific capital-return leaders, Amgen’s ability to maintain this level of distribution while simultaneously ...

Amgen has denied a request by the FDA to voluntarily withdraw its rare disease drug Tavneos from the market, the company said ...

Amgen believes that it can transcend the expected tradeoff between convenience and efficacy, anticipating that its ...

Amgen ended its collaboration with Kyowa Kirin on the experimental eczema drug rocatinlimab. The company received an FDA request to withdraw Tavneos, a treatment for rare blood vessel disease, due to ...

(Corrects paragraph 5 in February 5 story to say 2025 Prolia sales were $4.4 billion, not $1.05 billion) Feb 5 (Reuters) - ...

By Deena Beasley Feb 3 (Reuters) - Amgen on Tuesday reported fourth-quarter financial results that came in ahead of Wall ...

Signs that Amgen was cooling on rocatinlimab emerged last year. Asked about the market positioning of the antibody at a Citi ...

The biotechnology company reported a quarterly profit of $1.33 billion, attributing its boost in earnings to higher revenue ...

After review, Amgen is certain that Tavneos is effective and has a favorable benefit-risk profile. The company informed the ...

Amgen’s bad luck in lupus may finally be coming to an end. Daxdilimab, a monoclonal antibody acquired from Horizon ...

Amgen Balances Broad Growth With Manageable Risks in Latest Earnings Call ...

Amgen Inc. Buy thesis: strong pipeline, 12% Q3 2025 revenue growth and MariTide obesity upside. Click for this updated look at AMGN stock prospects.